Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Prelude Therapeutics Inc (PRLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRLD (1-star) is a SELL. SELL since 2 days. Profits (-12.22%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.75
1 Year Target Price $3.75
| 1 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.36% | Avg. Invested days 34 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.34M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 0.61 - 6.80 | Updated Date 06/30/2025 |
52 Weeks Range 0.61 - 6.80 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1999.67% |
Management Effectiveness
Return on Assets (TTM) -45.05% | Return on Equity (TTM) -81.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -34850760 | Price to Sales(TTM) 6.33 |
Enterprise Value -34850760 | Price to Sales(TTM) 6.33 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.54 | Shares Outstanding 43610200 | Shares Floating 18136236 |
Shares Outstanding 43610200 | Shares Floating 18136236 | ||
Percent Insiders 11.37 | Percent Institutions 69.69 |
Analyst Ratings
Rating 2 | Target Price 3.75 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Prelude Therapeutics Inc
Company Overview
History and Background
Prelude Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting critical signaling pathways implicated in cancer. The company went public in 2020.
Core Business Areas
- Discovery and Development: Focuses on identifying and developing small molecule drugs targeting cancer-related pathways.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Development: Investing in R&D to develop next generation compounds.
Leadership and Structure
Dr. Krishna Vaddi is the Chief Executive Officer. The company has a typical structure for a clinical-stage biopharmaceutical firm, with departments dedicated to research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- PRT2527: A CDK9 inhibitor in Phase 2 clinical development for various cancers. Market share is not yet established as the product is in clinical development. Competitors include companies developing CDK9 inhibitors such as Samus Therapeutics.
- PRT3645: A selective SMARCA2 degrader in Phase 1 clinical development. Market share is not yet established as the product is in clinical development. No immediate competitors are listed for SMARCA2 degraders, but other oncology companies targeting similar pathways exist.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It faces challenges from regulatory hurdles, clinical trial risks, and pricing pressures.
Positioning
Prelude Therapeutics is positioned as an innovative company focused on novel cancer therapies. Its competitive advantage lies in its specific target pathways and potential first-in-class or best-in-class drugs.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be billions of dollars annually. Prelude Therapeutics aims to capture a significant portion of this market with its targeted therapies. Specific TAM estimates for each drug candidate would depend on the cancer type and line of therapy.
Upturn SWOT Analysis
Strengths
- Innovative drug development pipeline
- Strong focus on specific cancer targets
- Experienced leadership team
Weaknesses
- Early-stage clinical development risks
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
Opportunities
- Potential for breakthrough therapies in unmet medical needs
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or collaborations
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other pharmaceutical companies
Competitors and Market Share
Key Competitors
- GILD
- MRK
- BMY
Competitive Landscape
Prelude Therapeutics faces competition from larger pharmaceutical companies with established oncology portfolios. Its success depends on demonstrating superior efficacy and safety with its novel drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by pipeline development, clinical trial initiation, and funding activities.
Future Projections: Future growth is dependent on the success of clinical trials and the potential for commercialization of its drug candidates. Analyst estimates should be consulted for specific revenue projections.
Recent Initiatives: Recent initiatives include progressing lead drug candidates through clinical trials and exploring potential partnerships.
Summary
Prelude Therapeutics is a clinical-stage biopharmaceutical firm with a promising pipeline of novel cancer therapies targeting specific signaling pathways. Its strength lies in its innovative approach and experienced team, but its success depends on overcoming clinical trial risks. Financial stability and potential partnerships will be crucial for long-term growth, but is currently in a competitive landscape with other established pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, press releases, and reputable financial news sources.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Prelude Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2020-09-25 | Founder, CEO & Director Dr. Krishna Vaddi D.V.M., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://preludetx.com |
Full time employees 131 | Website https://preludetx.com | ||
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.